More than 20 years ago oral tamoxifen was introduced to treat early and advanced breast cancers. Today it is also prescribed after primary treatment for early-stage breast cancer. The drug acts to block the female hormone estrogen, which promotes cancer growth.
Medical oncologists at Beaumont constantly monitor new drugs and protocols to find the best individual treatment plan for each patient. Beaumont's clinical trials are so well respected that the National Cancer Institute (NCI) has designated the hospital as a Community Oncology Research Program, where results from leading-edge clinical studies are integrated into the standard of care.
Today's research is every bit as crucial as the studies that first established the value of tamoxifen in treating breast cancer. As new information gleaned from research is quickly applied, patients benefit from the exciting discoveries that improve breast cancer diagnosis and treatment.
What is tamoxifen?
Tamoxifen (Nolvadex ® ) is a drug that reduces and/or stops the effects of estrogen (a female hormone) in the body. It was developed over 20 years ago and has been used to treat both advanced and early stage breast cancer. More recently, tamoxifen is being used as an adjuvant, or additional, therapy following primary treatment for early stage breast cancer.
Tamoxifen is taken by mouth in tablet form and is usually prescribed as a single daily dose.
How is tamoxifen used for breast cancer treatment?
As a breast cancer therapy, tamoxifen works against the effects of estrogen, which has been shown to promote the growth of breast cancer cells. It is often called an "anti-estrogen."
- As a treatment for breast cancer, the drug slows or stops the growth of cancer cells that are already present in the body.
- As adjuvant therapy, tamoxifen has been shown to help prevent the development and recurrence of breast cancer. Research has shown that when tamoxifen is used as adjuvant therapy for early stage breast cancer, it not only prevents the recurrence of the original cancer but also prevents the development of new cancers in the opposite breast, in many cases.
- As a preventative therapy, tamoxifen has been shown to help prevent the development of breast cancer in high-risk women. The Study of Tamoxifen and Raloxifene (STAR) trial, which evaluated the use of tamoxifen and another drug, raloxifene, in preventing breast cancer, found that raloxifene decreased the risk of invasive breast cancer equally as well as tamoxifen, but it did not protect as well against non-invasive cancers, such as lobular carcinoma in situ(LCIS) or ductal carcinoma in situ (DCIS). Raloxifene did, however, have a lower risk of uterine cancer and blood clots in the legs or lungs, compared to tamoxifen.
Additional benefits of tamoxifen
While tamoxifen acts against the effects of estrogen in breast tissue, it acts like estrogen in other body systems. According to the National Cancer Institute, women who take tamoxifen may share many of the beneficial effects of menopausal estrogen replacement therapy, such as a lowering of blood cholesterol and a slowing of bone loss (osteoporosis).
What are the possible side effects of tamoxifen?
Women considering taking tamoxifen should consult their physician. Different women experience side effects differently. Some of the more common side effects may include:
- hot flashes and sweats
- nausea and vomiting
- loss of appetite
- weight gain
- vaginal discharge
- irregular menstrual cycles
- vaginal dryness
- irritation of skin around the vagina
Less common side effects may include:
- blood clots
- eye problems
- uterine cancer
- other cancers
Some physicians and researchers caution, however, that tamoxifen therapy may not be appropriate for all women who are at increased risk for breast cancer. Consult your physician for more information regarding your individual case.
Other related medications
Medications recently approved by the US Food and Drug Administration (FDA), called aromatase inhibitors, are used to prevent the recurrence of breast cancer in postmenopausal women. These drugs, such as anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®), prevent estrogen production. Anastrozole is effective only in women who have not had previous hormonal treatment for breast cancer. Letrozole is effective in women who have previously been treated with tamoxifen. Possible side effects of these drugs include osteoporosis or bone fractures.
Another new drug for recurrent breast cancer is fulvestrant (Faslodex®). Also approved by the FDA, this drug eliminates the estrogen receptor rather than blocking it, as is the case with tamoxifen, letrozole, or anastrozole. This drug is used following previous antiestrogen therapy. Side effects for fulvestrant include hot flashes, mild nausea, and fatigue.